Combination treatment of tamoxifen with risperidone in breast cancer.

Tamoxifen has long been used and still is the most commonly used endocrine therapy for treatment of both early and advanced estrogen receptor-positive breast cancer in pre- and post-menopause women. Tamoxifen exerts its cytotoxic effect primarily through cytostasis which is associated with the accum...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Wei-Lan Yeh, Hui-Yi Lin, Hung-Ming Wu, Dar-Ren Chen
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2014
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/34c75769992945b38a66644ca816fce3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:34c75769992945b38a66644ca816fce3
record_format	dspace
spelling	oai:doaj.org-article:34c75769992945b38a66644ca816fce32021-11-18T08:17:41ZCombination treatment of tamoxifen with risperidone in breast cancer.1932-620310.1371/journal.pone.0098805https://doaj.org/article/34c75769992945b38a66644ca816fce32014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24886861/?tool=EBIhttps://doaj.org/toc/1932-6203Tamoxifen has long been used and still is the most commonly used endocrine therapy for treatment of both early and advanced estrogen receptor-positive breast cancer in pre- and post-menopause women. Tamoxifen exerts its cytotoxic effect primarily through cytostasis which is associated with the accumulation of cells in the G0/G1 phase of the cell cycle. Apoptotic activity can also be exerted by tamoxifen which involves cleavage of caspase 9, caspase 7, caspase 3, and poly-ADP-ribose polymerase (PARP). Down-regulation of anti-apoptotic proteins Bcl-2 and Bcl-xL and up-regulation of pro-apoptotic proteins Bax and Bak have also been observed. In addition, stress response protein of GRP 94 and GRP 78 have also been induced by tamoxifen in our study. However, side effects occur during tamoxifen treatment in breast cancer patients. Researching into combination regimen of tamoxifen and drug(s) that relieves tamoxifen-induced hot flushes is important, because drug interactions may decrease tamoxifen efficacy. Risperidone has been shown to be effective in reducing or eliminating hot flushes on women with hormonal variations. In this present study, we demonstrated that combination of tamoxifen with risperidone did not interfered tamoxifen-induced cytotoxic effects in both in vitro and in vivo models, while fluoxetine abrogated the effects of tamoxifen. This is the first paper suggesting the possibility of combination treatment of tamoxifen with risperidone in breast cancer patients, providing a conceivable resolution of tamoxifen-induced side effects without interfering the efficacy of tamoxifen against breast cancer.Wei-Lan YehHui-Yi LinHung-Ming WuDar-Ren ChenPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 6, p e98805 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Wei-Lan Yeh Hui-Yi Lin Hung-Ming Wu Dar-Ren Chen Combination treatment of tamoxifen with risperidone in breast cancer.
description	Tamoxifen has long been used and still is the most commonly used endocrine therapy for treatment of both early and advanced estrogen receptor-positive breast cancer in pre- and post-menopause women. Tamoxifen exerts its cytotoxic effect primarily through cytostasis which is associated with the accumulation of cells in the G0/G1 phase of the cell cycle. Apoptotic activity can also be exerted by tamoxifen which involves cleavage of caspase 9, caspase 7, caspase 3, and poly-ADP-ribose polymerase (PARP). Down-regulation of anti-apoptotic proteins Bcl-2 and Bcl-xL and up-regulation of pro-apoptotic proteins Bax and Bak have also been observed. In addition, stress response protein of GRP 94 and GRP 78 have also been induced by tamoxifen in our study. However, side effects occur during tamoxifen treatment in breast cancer patients. Researching into combination regimen of tamoxifen and drug(s) that relieves tamoxifen-induced hot flushes is important, because drug interactions may decrease tamoxifen efficacy. Risperidone has been shown to be effective in reducing or eliminating hot flushes on women with hormonal variations. In this present study, we demonstrated that combination of tamoxifen with risperidone did not interfered tamoxifen-induced cytotoxic effects in both in vitro and in vivo models, while fluoxetine abrogated the effects of tamoxifen. This is the first paper suggesting the possibility of combination treatment of tamoxifen with risperidone in breast cancer patients, providing a conceivable resolution of tamoxifen-induced side effects without interfering the efficacy of tamoxifen against breast cancer.
format	article
author	Wei-Lan Yeh Hui-Yi Lin Hung-Ming Wu Dar-Ren Chen
author_facet	Wei-Lan Yeh Hui-Yi Lin Hung-Ming Wu Dar-Ren Chen
author_sort	Wei-Lan Yeh
title	Combination treatment of tamoxifen with risperidone in breast cancer.
title_short	Combination treatment of tamoxifen with risperidone in breast cancer.
title_full	Combination treatment of tamoxifen with risperidone in breast cancer.
title_fullStr	Combination treatment of tamoxifen with risperidone in breast cancer.
title_full_unstemmed	Combination treatment of tamoxifen with risperidone in breast cancer.
title_sort	combination treatment of tamoxifen with risperidone in breast cancer.
publisher	Public Library of Science (PLoS)
publishDate	2014
url	https://doaj.org/article/34c75769992945b38a66644ca816fce3
work_keys_str_mv	AT weilanyeh combinationtreatmentoftamoxifenwithrisperidoneinbreastcancer AT huiyilin combinationtreatmentoftamoxifenwithrisperidoneinbreastcancer AT hungmingwu combinationtreatmentoftamoxifenwithrisperidoneinbreastcancer AT darrenchen combinationtreatmentoftamoxifenwithrisperidoneinbreastcancer
_version_	1718421914668498944

Combination treatment of tamoxifen with risperidone in breast cancer.

Ejemplares similares